Experts met 24^th-25^th May in Maastricht, The Netherlands, to discuss the latest news about PCSK9 science and research. The first in this series of presentations focuses on novel insights from the landmark PCSK9 inhibitor trials, as well as the inclisiran clinical trial programme.

Professor Andreas Zeiher (J. W. Goethe-University of Frankfurt, Germany) discusses the latest learnings from the ODYSSEY OUTCOMES trial with alirocumab.

Listen to the presentation here »

Professor Peter Sever (Imperial College London and International Centre for Circulatory Health, UK) overviews subgroup analyses from the FOURIER trial with evolocumab

Listen to the presentation here »

Professor Derick Raal (University of the Witwatersrand, Johannesburg, South Africa) updates on the clinical trial programme with inclisiran

Listen to the presentation here »

Education: the primary mission of PCSK9 Forum.

Don’t forget to check back for the latest updates to the PCSK9 Forum educational slide resource programme